

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL			
OMB Number:	3235-0104		
Estimated averag	e burden		
nours per respons	se 0.5		

#### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)										
Name and Address of Reporting Person- Brawer Michael	Statement (Month/Day/		2	Issuer Name <b>an</b> HRESHOLD					[THLD]	
(Last) (First) (Mic C/O THRESHOLD PHARMACEUTICALS, INC., 130 SEAPORT BOULEVARD, 5TH F	oddle)	10/30/2006		4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  Director				5. If Amendment, Date Original Filed(Month/Day/Year)		
(Street)			belo	below) below) Senior Medical Strategist				6. Individual or Joint/Group Filing(Check Applicable Line) X. Form filed by One Reporting Person		
REDWOOD CITY, CA 94063	(i)							Form filed by More than One Reporting Person		
	(ip)			lon-Derivat						
1.Title of Security (Instr. 4)		2. Amount of Sec Beneficially Own (Instr. 4)					4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Common Stock		10,11	9			D				
	respond to the co	ollection of in	formation c	ontained in t	his fo	orm are no	t requi	red to resp	SEC 1473 (7-02	
	m displays a cur erivative Securities	•			ants,	options, cor	vertib	le securities)		
		Beneficially O		uts, calls, warr Amount of nderlying	2 ( 1 1	4. Conversion or Exercise Price of Derivative	on 5. Fo De Se	Ownership rm of rivative curity:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
Table II - Do	erivative Securities  2. Date Exercisal Expiration Date	Beneficially O	3. Title and A Securities UnDerivative S	uts, calls, warr Amount of nderlying	1 1 2 2	4. Conversion or Exercise Price of	Fo De Se Di Inc	Ownership rm of rivative	Beneficial Ownership	
Table II - Do	2. Date Exercisal Expiration Date (Month/Day/Year)	Beneficially O ble and  Expiration Date	wned (e.g., p) 3. Title and A Securities Un Derivative S (Instr. 4)	Amount of nderlying ecurity	ares	4. Conversion or Exercise Price of Derivative	Fo De Se Di Inc	Ownership rm of rivative curity: rect (D) or direct (I)	Beneficial Ownership	
Table II - Do  1. Title of Derivative Security (Instr. 4)	2. Date Exercisal Expiration Date (Month/Day/Year)  Date Exercisable	Beneficially Oole and  Expiration Date  03/31/2013	wned (e.g., p) 3. Title and a Securities Un Derivative S (Instr. 4) Title Common	Amount or Number of Sh	la l	4. Conversion or Exercise Price of Derivative Security	Fo De Se Di Inc	Ownership rm of rivative curity: rect (D) or lirect (I) str. 5)	Beneficial Ownership	
Table II - Do  1. Title of Derivative Security (Instr. 4)  Stock Option (Right to Buy)	Date Exercisals (Month/Day/Year)  Date Exercisable  04/01/2003(2)	Beneficially O  ble and  Expiration Date  03/31/2013  05/11/2014	wned (e.g., p) 3. Title and a Securities Undervative S (Instr. 4) Title Common Stock Common	Amount of nderlying ecurity  Amount or Number of Sh	lares	4. Conversic or Exercise Price of Derivative Security \$ 0.16	Fo De Se Di Inc	Ownership rm of rivative curity: reet (D) or lirect (I) str. 5)	Beneficial Ownership	
Table II - Do  1. Title of Derivative Security (Instr. 4)  Stock Option (Right to Buy) (1)  Stock Option (Right to Buy) (1)	2. Date Exercisal Expiration Date (Month/Day/Year)  Date Exercisable  04/01/2003(2)  05/12/2005(4)	Expiration Date 03/31/2013 05/11/2014 12/13/2014	wned (e.g., p) 3. Title and A Securities Us Derivative S (Instr. 4)  Title  Common Stock  Common Stock  Common	Amount or Number of Sh	lares	4. Conversicor Exercise Price of Derivative Security  \$ 0.16	on 5. Fo De Se Di Inc	Ownership rm of rivative curity: rect (D) or lirect (I) str. 5)  D	Beneficial Ownership	
I. Title of Derivative Security (Instr. 4)  Stock Option (Right to Buy)  Stock Option (Right to Buy)  Stock Option (Right to Buy)  Stock Option (Right to Buy)	Date Exercisals Expiration Date (Month/Day/Year)  Date Exercisable  04/01/2003(2)  05/12/2005(4)	Expiration Date  03/31/2013  05/11/2014  12/13/2014  09/27/2016	wned (e.g., p) 3. Title and a Securities Uperivative S (Instr. 4)  Title  Common Stock  Common Stock  Common Stock  Common Stock  Common Stock  Common Stock	Amount or Number of Sh 6,072 (3)	2	4. Conversic or Exercise Price of Derivative Security  \$ 0.16  \$ 0.53	on 5. Fo De Se Di Inc	Ownership rm of rivative curity: rect (D) or lirect (I) str. 5)  D  D	Beneficial Ownership	

### Reporting Owners

	Relationships			
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Brawer Michael C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEAPORT BOULEVARD, 5TH FLOOR REDWOOD CITY, CA 94063			Senior Medical Strategist	

## Signatures

/s/ Kenneth B. Stratton, Attorney-in-fac		11/07/2006
--	--	------------

**Signature of Reporting Person	Date

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock option was granted pursuant to the Threshold Pharmaceuticals, Inc. 2004 Amended and Restated Equity Incentive Plan.
- (2) This stock option vests as to 1/4 of the shares underlying the option on April 1, 2003 and 1/48th of the total shares underlying the option vest and become exercisable on each monthly anniversary thereafter. 10,199 shares underlying this stock option have been exercised.
- (3) Reflects a 1 for 1.6469 reverse stock split effective as of January 26, 2005.
- (4) This stock option vests as to 1/4 of the shares underlying the option on May 12, 2005 and 1/48th of the total shares underlying the option vest and become exercisable on each monthly anniversary thereafter.
- (5) This stock option shall vest and become exercisable in 48 equal installments commencing on October 28, 2006.
- (6) This stock option shall vest and become exercisable on October 29, 2006.
- (7) This stock option shall vest as to 1/4 of the shares underlying the option on March 1, 2007 and 1/48th of the total shares underlying the option vest and become exercisable on each monthly anniversary thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Know all by these presents, that the undersigned hereby constitutes and appoints each of Harold E. Selick, Kenneth B. Stratton and Cathy Davis signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Threshold Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 1st day of November 2006.

/s/ Michael Brawer Signature Michael Brawer Print Name